Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Why it matters: Early efficacy could unlock a multi‑billion market, but cash constraints risk stalling development.
- CytomX Therapeutics reported encouraging Phase 1 results, with 3 of 10 patients achieving partial responses and a favorable safety profile.
- JPMorgan analysts downgraded the stock, emphasizing the limited cash runway despite the positive data.
- Wall Street commentary highlighted that the market is betting on a forthcoming Phase 2 trial to confirm the early promise.
CytomX Therapeutics’ shares surged after Phase 1 colorectal cancer data showed a 30% tumor‑shrinkage rate, yet weak Q1 earnings and a cash runway of just 12 months left investors wary of the runway.
